Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

ectibix arm. For patients with mutant KRAS tumors, median PFS was 7.3 months with Vectibix in combination with FOLFOX vs. 8.8 months with FOLFOX alone (hazard ratio 1.29, p=0.02). These data confirm previous findings when oxaliplatin-based chemotherapy and an anti-epidermal growth factor receptor (EGFR) antibody are combined in patients bearing tumors with activating KRAS mutations.

Consistent with the PFS data, an interim analysis of overall survival, a secondary endpoint, demonstrated a reduction in overall survival in patients with KRAS mutant tumors receiving Vectibix. The median overall survival for patients with KRAS wild-type mCRC has not yet been reached. Long-term follow-up for survival continues and the primary analysis is expected in the fourth quarter of 2009.

Adverse event rates were comparable across arms with the exception of known toxicities associated with anti-epidermal growth factor receptor (EGFR) therapy such as rash, diarrhea and hypomagnesemia. Vectibix-related grade 3 infusion reactions were reported for two patients (less than 1 percent).

Originally designed to compare the treatment effect in the overall population, the study was amended to analyze outcomes with respect to the presence or absence of activating mutations in KRAS in the tumor itself. Tumor KRAS status was ascertained in 93 percent of the 1,183 patients enrolled in the trial, the highest percentage ever reported. Tumor KRAS tests were finalized after the completion of enrollment and prior to the primary analysis.

Earlier this week, data were presented from the '181' trial which showed that Vectibix administered in combination with FOLFIRI (an irinotecan-based chemotherapy) prolonged PFS by 2 months in patients with KRAS wild-type mCRC, compared to treatment with FOLFIRI alone (Abstract Number 14LBA).

Webcast Informa
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... WORTH, Texas, March 22, 2012  The Board of Directors of ... innovator in advanced wound care solutions, announced today that Robert ... of the Company.  In addition, Scott A. Haire has resigned ... Executive Officer of the Company, and Deborah Jenkins Hutchinson has ...
... 22, 2012  Argon Medical Devices, Inc. announced today ... catheter, licensed from Rex Medical, LP, designed to ... treatments. "UltraStream provides clinicians with an ... life for their patients," commented George Leondis, President ...
Cached Medicine Technology:Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 2Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 3Argon Medical Devices Announces The Launch of a Unique New Chronic Hemodialysis Catheter 2
(Date:9/16/2014)... September 15, 2014A prospective study that compared patient-reported ... with bone metastases demonstrates that single fraction radiation ... fraction radiation therapy (MFRT) when pain, function and ... presented today at the American Society for Radiation ... indicates that improvements in patients, pain, function and ...
(Date:9/16/2014)... Poster and Poster Discussion abstracts to be presented at ... Wednesday, 17 September 2014 at 12:00 (CEST) to give ... from the European medical oncology Congress, under the leading ... at the point where genuinely targeted therapy is now ... medicine means we are all working towards a common ...
(Date:9/16/2014)... PA (PRWEB) September 16, 2014 ... Pain Management practice by Ranking Arizona magazine, has selected ... implementation across its enterprise. , With TPC seeing ... a vast data repository that was managed through “home ... both the management and clinical leadership teams. “Our ...
(Date:9/16/2014)... Albany, New York (PRWEB) September 16, 2014 ... intelligence firm states that the global facial care market ... billion by 2019. The report, titled ‘Facial Care Market ... Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming up with ... become the Presenting Sponsor of the 2014-15 and 2015-16 ... wellness partner. As the Presenting Sponsor for the next ... name inclusion on all Lightning advertising campaigns and materials ... a sponsorship partner of the Lightning since 2011, and ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3
... business of recruiting,university students and new graduates is ... on this talent pool to,refresh the workforce with ... changed their university recruiting methods and programs,in decades ... a leading,pharmaceutical research firm., The study analyzes ...
... need to be aware of the connection, study says ... between diabetes and depression apparently cuts both ways: Not ... a heightened risk for developing depression, individuals with depression ... research revelation suggests that both doctors and patients need ...
... Foundation,announced the winners of its annual "Healthy Communities ... 10 at its offices in Edison, N.J.,Twelve New ... year,s,calendar and each received an iPOD shuffle., ... importance,of a healthy lifestyle and promotes awareness of ...
... Million in Savings in Past 4 Years, HARRISBURG, ... saving taxpayer funds, they should support,the Department of Public ... less for prescription drugs for children and families who ... Welfare,Estelle B. Richman said today., "Every budget season ...
... the University of Pennsylvania School of Medicine found that ... cell and developmental biology leads to an increase in ... therapies for lung-tissue repair after injury or disease. The ... of print publication in Nature Genetics . , ...
... Continues to Draw Top Research Institutes,Talent, and Corporate Labs That Are Looking ... ... Future, SAN DIEGO, June 17 /Xinhua-PRNewswire/ -- Singapore,s investment ... the fastest growing bioclusters in the world. R&D spending in the,biomedical sciences ...
Cached Medicine News:Health News:Best Practices: Achieving Excellence in Staffing and Recruiting Methods 2Health News:Diabetes and Depression Go Hand-in-Hand 2Health News:Diabetes and Depression Go Hand-in-Hand 3Health News:AMERIGROUP Foundation Announces Winners of 'Healthy Communities Art Project' 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 3Health News:Penn researchers find key developmental pathway activates lung stem cells 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 3Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 4Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 5Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 6
... ACS allows visualization of virtually the ... essentially coaxial positioning of the lens on ... detachment surgery, repairing giant retinal tears, diagnosing ... examining the peripheral retina in a vitreous ...
... somewhat higher magnification and increased ... best suited for detailed visualization ... Central Retinal is ideal for ... membrane peeling in proliferative vitreoretinopathy ...
... MiniQuad allows visualization of virtually the ... with essentially coaxial positioning of the ... excellent for retinal detachment surgery, repairing ... anterior proliferative vitreoretinopathy and for examining ...
... Lens enhances iridectomy procedures by providing ... conventional iridectomy lens designs) with exceptional ... this lens has been increased from ... The MagPlus comes standard with LaserWindow ...
Medicine Products: